154 related articles for article (PubMed ID: 30257367)
1. CXCL5, the upregulated chemokine in patients with uterine cervix cancer, in vivo and in vitro contributes to oncogenic potential of Hela uterine cervix cancer cells.
Feng X; Zhang D; Li X; Ma S; Zhang C; Wang J; Li Y; Liang L; Zhang P; Qu Y; Zhang Z; Yang Z; Xiang Y; Zhang W; Wang S; Shao W; Wang W
Biomed Pharmacother; 2018 Nov; 107():1496-1504. PubMed ID: 30257367
[TBL] [Abstract][Full Text] [Related]
2. CXCL3 overexpression promotes the tumorigenic potential of uterine cervical cancer cells via the MAPK/ERK pathway.
Qi YL; Li Y; Man XX; Sui HY; Zhao XL; Zhang PX; Qu XS; Zhang H; Wang BX; Li J; Qi SF; Jia LL; Luan HY; Zhang CB; Wang WQ
J Cell Physiol; 2020 May; 235(5):4756-4765. PubMed ID: 31667838
[TBL] [Abstract][Full Text] [Related]
3. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer.
Chen C; Xu ZQ; Zong YP; Ou BC; Shen XH; Feng H; Zheng MH; Zhao JK; Lu AG
Cell Death Dis; 2019 Feb; 10(3):178. PubMed ID: 30792394
[TBL] [Abstract][Full Text] [Related]
4. High C-X-C motif chemokine 5 expression is associated with malignant phenotypes of prostate cancer cells via autocrine and paracrine pathways.
Qi Y; Zhao W; Li M; Shao M; Wang J; Sui H; Yu H; Shao W; Gui S; Li J; Jia X; Jiang D; Li Y; Zhang P; Wang S; Wang W
Int J Oncol; 2018 Jul; 53(1):358-370. PubMed ID: 29749439
[TBL] [Abstract][Full Text] [Related]
5. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways.
Zhao J; Ou B; Han D; Wang P; Zong Y; Zhu C; Liu D; Zheng M; Sun J; Feng H; Lu A
Mol Cancer; 2017 Mar; 16(1):70. PubMed ID: 28356111
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer.
Li A; King J; Moro A; Sugi MD; Dawson DW; Kaplan J; Li G; Lu X; Strieter RM; Burdick M; Go VL; Reber HA; Eibl G; Hines OJ
Am J Pathol; 2011 Mar; 178(3):1340-9. PubMed ID: 21356384
[TBL] [Abstract][Full Text] [Related]
8. Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
Cui D; Zhao Y; Xu J
Cancer Biol Ther; 2019; 20(5):608-616. PubMed ID: 30404567
[TBL] [Abstract][Full Text] [Related]
9. The CXCL5/CXCR2 axis contributes to the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells by activating ERK/GSK-3β/snail signalling.
Qiu WZ; Zhang HB; Xia WX; Ke LR; Yang J; Yu YH; Liang H; Huang XJ; Liu GY; Li WZ; Xiang YQ; Kang TB; Guo X; Lv X
J Exp Clin Cancer Res; 2018 Apr; 37(1):85. PubMed ID: 29665837
[TBL] [Abstract][Full Text] [Related]
10. High expression level of CXCL1/GROα is linked to advanced stage and worse survival in uterine cervical cancer and facilitates tumor cell malignant processes.
Man X; Yang X; Wei Z; Tan Y; Li W; Jin H; Wang B
BMC Cancer; 2022 Jun; 22(1):712. PubMed ID: 35764974
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
[No Abstract] [Full Text] [Related]
12. The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis.
Romero-Moreno R; Curtis KJ; Coughlin TR; Miranda-Vergara MC; Dutta S; Natarajan A; Facchine BA; Jackson KM; Nystrom L; Li J; Kaliney W; Niebur GL; Littlepage LE
Nat Commun; 2019 Sep; 10(1):4404. PubMed ID: 31562303
[TBL] [Abstract][Full Text] [Related]
13. CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9.
Gao Y; Guan Z; Chen J; Xie H; Yang Z; Fan J; Wang X; Li L
Int J Oncol; 2015 Aug; 47(2):690-700. PubMed ID: 26058729
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma.
Zhou SL; Dai Z; Zhou ZJ; Wang XY; Yang GH; Wang Z; Huang XW; Fan J; Zhou J
Hepatology; 2012 Dec; 56(6):2242-54. PubMed ID: 22711685
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between head and neck cancer cells and lymphatic endothelial cells promotes tumor metastasis via CXCL5-CXCR2 signaling.
Lee BS; Jang JY; Seo C; Kim CH
FASEB J; 2021 Jan; 35(1):e21181. PubMed ID: 33231340
[TBL] [Abstract][Full Text] [Related]
16. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer.
Kawamura M; Toiyama Y; Tanaka K; Saigusa S; Okugawa Y; Hiro J; Uchida K; Mohri Y; Inoue Y; Kusunoki M
Eur J Cancer; 2012 Sep; 48(14):2244-51. PubMed ID: 22197219
[TBL] [Abstract][Full Text] [Related]
17. A C-X-C Chemokine Receptor Type 2-Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis.
Zhou Z; Xia G; Xiang Z; Liu M; Wei Z; Yan J; Chen W; Zhu J; Awasthi N; Sun X; Fung KM; He Y; Li M; Zhang C
Clin Cancer Res; 2019 Jun; 25(11):3317-3328. PubMed ID: 30796034
[TBL] [Abstract][Full Text] [Related]
18. Serum miR-486-5p as a diagnostic marker in cervical cancer: with investigation of potential mechanisms.
Li C; Zheng X; Li W; Bai F; Lyu J; Meng QH
BMC Cancer; 2018 Jan; 18(1):61. PubMed ID: 29316891
[TBL] [Abstract][Full Text] [Related]
19. Osteocytes support bone metastasis of melanoma cells by CXCL5.
Jia Y; Zhang F; Meng X; Andreev D; Lyu P; Zhang W; Lai C; Schett G; Bozec A
Cancer Lett; 2024 May; 590():216866. PubMed ID: 38589005
[TBL] [Abstract][Full Text] [Related]
20. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target.
Zhang W; Wang H; Sun M; Deng X; Wu X; Ma Y; Li M; Shuoa SM; You Q; Miao L
Cancer Commun (Lond); 2020 Mar; 40(2-3):69-80. PubMed ID: 32237072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
